vVARDIS, a developer of drill-free dental caries treatment products, has received Strategic Investment, joining the ranks of global unicorns.

Source: vVARDIS official website

DentalGoodNews｜On April 15, 2026, Swiss dental medical technology company vVARDIS announced that it has received a strategic minority equity investment from funds managed by Apollo (Apollo Funds). vVARDIS stated that this transaction values the company at over $1 billion, officially making it a unicorn and one of the few privately held healthcare companies in Europe valued at over $1 billion.

According to the company's disclosure, the agreement stipulates that vVARDIS founder and co-CEOs Dr. Haley Abivardi and Dr. Goly Abivardi retain an absolute majority stake in the company. The funds obtained will primarily support the company's next phase of global growth and commercial expansion, particularly the ongoing global promotion of its core product, the Curodont™ series.

Source: vVARDIS official website

According to the company's disclosure, vVARDIS's core competitiveness lies in its patented bio-inspired P11-4 peptide technology, which supports enamel repair by forming crystalline mineral structures in damaged areas, offering dental professionals a minimally invasive restorative alternative to traditional drilling. The company claims that Curodont™ is the first and only commercialized peptide-based non-invasive formulation and states that it has been clinically proven for the treatment of dental caries/early-stage cavities.

Additionally, the company stated that since launching Curodont™ Repair Fluoride Plus in the U.S. market two years ago, the product has been used to treat approximately 3 million teeth, and it is now adopted by nearly 20% of general dental clinics nationwide. Notably, according to previous reports by DENTALGOODNEWS (Leading Dental Industry Media, DGN), vVARDIS received an additional $50 million investment from OrbiMed in July 2025, bringing its cumulative funding to $85 million at that time.

The company stated that dental caries is currently the most prevalent non-communicable disease worldwide, affecting nearly 90% of U.S. adults, and vVARDIS targets a U.S. market opportunity of over $30 billion. Apollo partner Jeremy Honeth commented that this investment aims to support vVARDIS's continued expansion in key markets in the U.S. and Europe, bringing this restorative therapy to more clinics and patients globally.